NCT06223568进行中（未招募）2 期
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 70
- 试验地点
- 2
- 主要终点
- Determine the rate of pCR with NAC (DC) alone or in combination with PRGN-2009 (DCP) in participants with newly diagnosed HPV-associated OPSCC
研究概览
简要总结
Background:
Throat cancer is a common tumor that can occur in people infected with the human papilloma virus (HPV). Most people with this cancer survive more than 5 years with standard chemotherapy drugs plus radiation. But radiation can cause serious adverse effects. Researchers believe that adding a vaccine (PRGN-2009) to this drug therapy may improve survival without the need for radiation.
Objective:
To test a study vaccine combined with standard chemotherapy in patients with HPV-associated throat cancers.
Eligibility:
People aged 18 years and older with newly diagnosed throat cancer associated with HPV.
Design:
Participants will be screened. They will have a physical exam and blood tests. They will have imaging scans and tests of their heart function and hearing. They will provide a sample of tissue from their tumor. A recent sample may be used; if none is available, a new sample will be taken.
All participants will get two common drugs for treating cancer. These drugs are given through a tube attached to a needle inserted into a vein in the arm. Participants will receive these drugs on the first day of three 3-week cycles.
Half of the participants will also get the vaccine. PRGN-2009 is injected under the skin in the arm. They will get these shots 4 times: 7 days before the start of the first cycle and on the 11th day of each cycle.
Participants will have standard surgery to remove their tumors 3 to 6 weeks after completing the study treatment. They will have follow-up visits 3, 6, 12, and 24 months after their surgery.
...
详细描述
Background:
- Human papilloma virus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is among the most common HPV-associated malignancies and the incidence is increasing. The prognosis is favorable with >80% 5-year recurrence free survival observed following standard anti-cancer treatments that consist of surgery followed by adjuvant post-operative radiation therapy (PORT) or concurrent chemoradiation (CRT).
- Although oncologic control is excellent, these standard-of-care treatments often lead to radiation-associated long-term toxicity that includes tissue fibrosis resulting in long-term swallow dysfunction and poor quality of life (QOL).
- Neoadjuvant chemotherapy (NAC) followed by surgery has decades of real-world data, with clinical-to-pathologic downstaging or pathologic complete response (pCR) being observed in most patients, >90% 5-year survival, and complete avoidance of radiation treatment in >95% of patients.
- The rate of pCR, clinical-to-pathologic downstaging, and functional outcomes after NAC followed by surgery have not been studied in a formal, prospective clinical study.
- A pilot correlative study of NAC with docetaxel and cisplatin (DC) in patients with newly diagnosed HPV-associated OPSCC conducted at the NIH revealed induction of HPV-specific T cell immunity that associates with clinical outcome (18DC0051).
- PRGN-2009 is a gorilla adenoviral therapeutic vaccine designed to enhance HPV 16/18- specific T-cell responses. The safety and efficacy of PRGN-2009 in patients with newly diagnosed HPV-associated OPSCC have been studied at the NIH Clinical Center (NCT04432597).
- Pre-clinical data indicate that chemotherapy can remodel the tumor microenvironment and enhance immunotherapy, suggesting that the combination of DC and PRGN-2009 may enhance anti-tumor immunity and the rate of pCR beyond that observed with DC alone.
Objective:
-To determine the rate of pCR with NAC (DC) alone or in combination with PRGN-2009 (DCP) in participants with newly diagnosed HPV-associated OPSCC.
Eligibility criteria:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •INCLUSION CRITERIA:
- •Histologically or cytologically confirmed surgically resectable newly diagnosed stage I (cT1-2, N0-1) or II (T1-3, N0-2), M0 oropharyngeal squamous cell carcinoma. Note: Pathological report of cancer diagnosis may be from the primary tumor or from a metastatic cervical lymph node.
- •History of HPV-positive status determined by a standard-of-care HPV testing. Note: All participants with high-risk HPV serotypes are eligible.
- •Age >= 18 years.
- •ECOG performance status <=
- •Individuals who smoke currently must smoke <10 pack years. Note: Former smokers with any pack-year history are eligible if quit smoking >10 years before study treatment initiation. Former smokers who quit <10 years before study treatment initiation must have smoked <10 pack years.
- •Planned for cancer removal surgery per standard of care (SOC) and individual had agreed for the cancer removal surgery.
- •Individuals must have adequate organ and marrow function as defined below:
- •Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
- •Hemoglobin (Hgb) >= 9.0 g/dL
- •Platelet count >= 100 x 10^9/L
- •Creatinine <= 1.2 x upper limit of normal (ULN) OR calculated creatinine clearance >=55 mL/min/1.73m^2 by Cockcroft-Gault formula
- •Total bilirubin <= 1 x ULN, or <= 3 x ULN in patients with known or suspected Gilbert's Syndrome
- •Alanine aminotransferase (ALT) <= 1.5 x ULN
- •Aspartate aminotransferase (AST) <= 1.5 x ULN
- •Individuals serologically positive for human immunodeficiency virus (HIV) must:
- •be on effective anti-retroviral therapy for at least 4 weeks; and
- •have undetectable viral load; and
- •have the CD4 count >=200 cells/microL; and
- •have no reported opportunistic infections or Castleman s disease within 12 months prior to study treatment initiation
- •Individuals serologically positive for Hepatitis C virus (HCV) or Hepatitis B virus (HCB) must have an undetectable viral load.
- •Individuals of child-bearing potential (IOCBP) must agree to use a highly effective method of contraception (hormonal, intrauterine device (IUD), surgical sterilization, abstinence) for the duration of the study treatment and up to 2 months after the last dose of PRGN-2009 and an effective method of contraception (barrier, hormonal, intrauterine device (IUD), surgical sterilization, abstinence) for 14 months after the last dose of cisplatin/docetaxel. Note: IOCBP is defined as any woman who has experienced menarche and has not had a hysterectomy or bilateral oophorectomy or is not postmenopausal (amenorrheic 12 months or more following cessation of exogenous hormonal treatments; if <50 years old and need follicle stimulating hormone [FSH] in the post-menopausal range).
- •Men must agree to use a highly effective method of contraception (surgical sterilization, abstinence) for the duration of the study treatment and up to 2 months after the last dose of PRGN-2009 and an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to 11 months after the last dose of the study drug(s). We also will recommend men on treatment with PRGN-2009 with female partners of childbearing potential ask female partners to be on highly effective birth control (hormonal, intrauterine device (IUD), surgical sterilization) during PRGN-2009 treatment and 2 months after that.
- •Breastfeeding individuals must be willing to discontinue breastfeeding from study treatment initiation through 2 months after the last dose of the study drug(s).
- •Individuals must have a tumor site that is amenable to biopsy and be willing to undergo pre- treatment biopsy for research purposes.
- •Individuals must be willing to undergo pre-treatment PET/CT imaging study.
- •The ability of an individual to understand and the willingness to sign a written informed consent document.
排除标准
- •Peripheral motor or sensory neuropathy > Grade 2 per Common Terminology Criteria for Adverse Events (CTCAE) v.5 at screening.
- •Prior therapy with an investigational drug, live vaccine, chemotherapy, immunotherapy, or any prior radiotherapy (except for palliative bone-directed therapy) within 4 weeks prior to the first study drug administration. Note: Participants may continue adjuvant hormonal therapy in the setting of a definitively treated cancer (e.g., breast).
- •Prior therapy with any medications or substances that are moderate or strong inducers or moderate or strong inhibitors of cytochrome P450 (CYP3A) https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table2-2,table3-3,table5-2 within 2 weeks prior to the first study drug administration.
- •History of allergic reactions attributed to compounds of similar chemical or biological composition to drugs used in the study.
- •Systemic (intravenous or oral) glucocorticoid (except for physiologic doses of corticosteroids, i.e., <= the equivalent of prednisone 10 mg/day) or other immunosuppressors such as azathioprine or cyclosporin A within 1 week prior to study treatment initiation. Note: Glucocorticoids as premedication for contrast-enhanced studies are allowed.
- •Second malignancy active within the previous 2 years except for indolent or locally curable malignancy that is currently considered cured and/or does not require an additional standard of care treatment, such as, but not limited to, cutaneous basal or squamous cell carcinoma, superficial bladder cancer, or cervical carcinoma in situ, or an incidental histological finding of prostate cancer or differentiated thyroid cancer.
- •Prior allogenic tissue/solid organ transplant.
- •History of heart failure.
- •Positive beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test performed in females of childbearing potential at screening.
- •Uncontrolled intercurrent illness or medical condition(s) evaluated by medical history and physical exam or situations that are not stable (e.g., recent hospitalization, Emergency Room visit or undergoing medication changes) that would potentially increase risk for the participant.
研究组 & 干预措施
Arm 2
Experimental
DCP (docetaxel + cisplatin + PRGN-2009)
干预措施: PRGN-2009 (Drug)
Arm 1
Experimental
DC (docetaxel + cisplatin)
干预措施: Docetaxel (Drug)
Arm 2
Experimental
DCP (docetaxel + cisplatin + PRGN-2009)
干预措施: Docetaxel (Drug)
Arm 1
Experimental
DC (docetaxel + cisplatin)
干预措施: Cisplatin (Drug)
Arm 2
Experimental
DCP (docetaxel + cisplatin + PRGN-2009)
干预措施: Cisplatin (Drug)
结局指标
主要结局
Determine the rate of pCR with NAC (DC) alone or in combination with PRGN-2009 (DCP) in participants with newly diagnosed HPV-associated OPSCC
时间窗: 6 months
The pCR rates will be determined on each arm and will be reported along with a 95% confidence interval. The two rates will be compared using a one-sided Fisher s exact test.
次要结局
- Determine the toxicity observed with DC and DCP(Day 1 (all arms) and day 11 (Arm 2 only) of every cycle and Day -7 of C1 (Arm 2 only), and at Safety Follow-Up visit which occurs 14 (+14) days after the study agent (s) was/were last administered. 3-month follow-up visit and beyond.)
- Determine 2-year recurrence-free survival (RFS) observed with DC and DCP(3, 6, 12, 24 months after surgery per SOC until recurrence.)
研究者
研究点 (2)
Loading locations...
相似试验
撤回
2 期
Study Using Pharmacogenetics to Select Treatment for Head and Neck CancerHead and Neck CancerNCT00881114Georgetown University
招募中
2 期
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck CancerLocally Advanced Head and Neck CancerNCT03532737Kuwait Cancer Control Center50
尚未招募
3 期
TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal CarcinomaHigh Risk Locally Advanced Nasopharyngeal CarcinomaNCT06561763Sun Yat-sen University416
Unknown
2 期
FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric CancerEffects of ChemotherapySurgeryGastric CancerNCT02226380Peking Union Medical College Hospital75
已完成
2 期
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer PatientsEsophageal Squamous Cell CarcinomaNCT01258192Zhejiang Cancer Hospital35